Stockscreener 앱 받기
2.80
1.75%
-0.05
시간 외 거래:
2.80
전일 마감가:
$2.85
열려 있는:
$2.81
하루 거래량:
1.08M
Relative Volume:
0.49
시가총액:
$377.98M
수익:
-
순이익/손실:
$-35.47M
주가수익비율:
-4.9123
EPS:
-0.57
순현금흐름:
$-124.27M
1주 성능:
-7.89%
1개월 성능:
+2.19%
6개월 성능:
+254.79%
1년 성능:
+79.49%
1일 변동 폭
$2.705
$2.825
1주일 범위
$2.705
$3.27
52주 변동 폭
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
명칭
Prokidney Corp
전화
336-999-7028
주소
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
PROK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.80 | 387.54M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 개시 | JP Morgan | Neutral |
| 2024-09-10 | 개시 | Guggenheim | Buy |
| 2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-07-25 | 개시 | BTIG Research | Buy |
| 2022-12-21 | 개시 | Jefferies | Buy |
| 2022-11-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 개시 | UBS | Buy |
| 2022-10-14 | 개시 | Citigroup | Buy |
| 2022-09-23 | 개시 | BofA Securities | Buy |
| 2022-09-02 | 개시 | Evercore ISI | Outperform |
모두보기
Prokidney Corp 주식(PROK)의 최신 뉴스
ProKidney (NASDAQ:PROK) Stock Price Down 9%Time to Sell? - MarketBeat
What candlestick patterns are forming on ProKidney Corp.July 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - newser.com
Will ProKidney Corp. stock beat EPS estimatesEarnings Miss & Daily Entry Point Alerts - newser.com
What data driven models say about ProKidney Corp.’s future2025 Breakouts & Breakdowns & Free Reliable Trade Execution Plans - newser.com
Is now a turning point for ProKidney Corp.Quarterly Performance Summary & AI Powered Buy and Sell Recommendations - newser.com
Is ProKidney Corp. stock poised for growthWeekly Trade Summary & Daily Volume Surge Signals - newser.com
Automated trading signals detected on ProKidney Corp.Weekly Trend Recap & AI Driven Stock Movement Reports - newser.com
Heatmap analysis for ProKidney Corp. and competitorsJuly 2025 Fed Impact & Scalable Portfolio Growth Methods - newser.com
What valuation multiples suggest for ProKidney Corp. stockJuly 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
What to expect from ProKidney Corp. in the next 30 daysPortfolio Profit Report & Trade Opportunity Analysis - newser.com
Visual analytics tools that track ProKidney Corp. performancePortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Will ProKidney Corp. stock recover faster than peersShare Buyback & Verified Momentum Stock Watchlist - newser.com
Will ProKidney Corp. stock go up soonRisk Management & Long-Term Safe Investment Ideas - newser.com
How ProKidney Corp. stock performs in stagflationSwing Trade & Community Trade Idea Sharing - newser.com
What technical charts say about ProKidney Corp. stockJuly 2025 EndofMonth & Growth Oriented Trading Recommendations - newser.com
ProKidney (NASDAQ:PROK) Shares Down 8.2%Should You Sell? - MarketBeat
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference - The Manila Times
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 - Investing News Network
Prokidney Corp (PROK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):